Results of a phase I trial with Haploidentical mbIL‐21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase I trial demonstrates safe complete remissions from haploidentical NK cells in refractory AML, indicating a feasible bridge to transplantation.

Infusions of haploidentical natural killer cells induced complete remission in 58.3% of patients with multiply relapsed acute myeloid leukemia without causing any toxicity.
In this phase I clinical trial, 12 refractory patients received mbIL-21 expanded donor cells, resulting in a 1-year overall survival rate of 41.7% and no graft-versus-host disease.
Higher levels of inhibitory KIR and elevated interferon gamma correlated with remission, indicating expanded donor cell infusions may provide an effective bridge to transplantation.

Ciurea et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Phase I trial demonstrates safe complete remissions from haploidentical NK cells in refractory AML, indicating a feasible bridge to transplantation.

Infusions of haploidentical natural killer cells induced complete remission in 58.3% of patients with multiply relapsed acute myeloid leukemia without causing any toxicity.
In this phase I clinical trial, 12 refractory patients received mbIL-21 expanded donor cells, resulting in a 1-year overall survival rate of 41.7% and no graft-versus-host disease.
Higher levels of inhibitory KIR and elevated interferon gamma correlated with remission, indicating expanded donor cell infusions may provide an effective bridge to transplantation.

Ciurea et al. (2024) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark